RBR-10xjp5tz
Recruiting
未知
Three-dimensional evaluation of biological effects on the craniofacial complex of surgically assisted rapid maxillary expansion (SARME) and mini-implants (MARPE) in adults - MARPE SARME MARPE - mini-implant assisted rapid palatal expander SARME - surgically assisted rapid maxillary expansion
Faculdade de Odontologia Universidade de São Paulo0 sitesFebruary 11, 2022
Conditionsdentofacial anomalies
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- dentofacial anomalies
- Sponsor
- Faculdade de Odontologia Universidade de São Paulo
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Brazilian nationality; Craniofacial growth completed; Transverse maxillary deficiency, with or without posterior crossbite, unilateral or bilateral; Age between 25 and 45 years old, male and female; permanent dentition, with at least the first or second permanent upper molars; Good dental conditions and periodontal health. No history of previous orthodontic treatment; Absence of systemic diseases or congenital deformities. Transverse maxillary discrepancy greater than 4mm and less than 10mm
Exclusion Criteria
- •Absence of permanent maxillary first molars and pre\- molars. Presence of deformities or congenital syndromes; Presence of cleft lip and palate; Presence of systemic diseases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study of safety and efficacy of three-dimensional prostate biopsy method for patients with suspected prostate cancersuspected prostate cancerJPRN-UMIN000015331Department of Urology, Keio University School of Medicine200
Completed
Not Applicable
Influence of orthopedic therapy in cleft lip palate patientHealth Condition 1: null- Cleft patients undergoing skeletal correctionCTRI/2017/02/007964Yenepoya University36
Active, not recruiting
Phase 1
Venglustat in Combination with Cerezyme in Adult and Pediatric Patients with Gaucher Disease Type 3Gaucher disease type 3MedDRA version: 20.0Level: PTClassification code 10075699Term: Gaucher's disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2020-003120-17-FRGenzyme Corporation12
Active, not recruiting
Phase 1
Venglustat in Combination with Cerezyme in Adult and Pediatric Patients with Gaucher Disease Type 3Gaucher disease type 3MedDRA version: 20.0Level: PTClassification code 10075699Term: Gaucher's disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2020-003120-17-HUGenzyme Corporation12
Active, not recruiting
Phase 1
Venglustat in Combination with Cerezyme in Adult and Pediatric Patients with Gaucher Disease Type 3Gaucher disease type 3MedDRA version: 20.0Level: PTClassification code 10075699Term: Gaucher's disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2020-003120-17-SEGenzyme Corporation12